Duke University Medical Center, Department of Medicine, Division of Cellular Therapy, Durham, North Carloina, 27705, USA.
Biol Blood Marrow Transplant. 2010 Aug;16(8):1107-14. doi: 10.1016/j.bbmt.2010.02.018. Epub 2010 Feb 24.
Infusing natural killer (NK) cells following transplantation may allow less infections and relapse with little risk of acute graft-versus-host disease (aGVHD). We delivered 51 total NK cell-enriched donor lymphocyte infusions (DLIs) to 30 patients following a 3-6/6 HLA matched T cell-depleted nonmyeloablative allogeneic transplant. The primary endpoint of this study was feasibility and safety. Eight weeks following transplantation, donor NK cell-enriched DLIs were processed using a CD56(+) selecting column with up to 3 fresh infusions allowed. Toxicity, relapse, and survival were monitored. T cell phenotype, NK cell functional recovery, and KIR typing were assessed for association with outcomes. Fourteen matched and 16 mismatched transplanted patients received a total of 51 NK cell-enriched DLIs. Selection resulted in 96% (standard deviation [SD] 8%) purity and 83% (SD 21%) yield in the matched setting and 97% (SD 3%) purity and 77% (SD 24%) yield in the mismatched setting. The median number of CD3(-) CD56(+) NK cells infused was 10.6 (SD 7.91) x 10(6) cells/kg and 9.21 (SD 5.6) x 10(6) cells/kg, respectively. The median number of contaminating CD3(+)CD56(-) T cells infused was .53 (1.1) x 10(6) and .27 (.78) x 10(6) in the matched and mismatched setting, respectively. Only 1 patient each in the matched (n = 14) or mismatched (n = 16) setting experienced severe aGVHD with little other toxicity attributable to the infusions. Long-term responders with multiple NK cell-enriched infusions and improved T cell phenotypic recovery had improved duration of responses (p = .0045) and overall survival (OS) (P = .0058). A 1-step, high-yield process is feasible, and results in high doses of NK cells infused with little toxicity. NK cell-enriched DLIs result in improved immune recovery and outcomes for some. Future studies must assess whether the improved outcomes are the direct result of the high doses and improved NK cell function or other aspects of immune recovery.
输注自然杀伤 (NK) 细胞可能有助于减少感染和复发,同时降低急性移植物抗宿主病 (aGVHD) 的风险。我们对 30 名接受 HLA 配型 3/6 个点 T 细胞清除非清髓性异基因移植的患者进行了 51 次总 NK 细胞富集供者淋巴细胞输注 (DLI)。本研究的主要终点是可行性和安全性。移植后 8 周,使用 CD56(+)选择柱处理供者 NK 细胞富集 DLI,最多允许 3 次新鲜输注。监测毒性、复发和生存情况。评估 T 细胞表型、NK 细胞功能恢复和 KIR 分型与结果的关系。14 名匹配和 16 名不匹配的移植患者共接受了 51 次 NK 细胞富集 DLI。在匹配组中,选择后纯度为 96%(标准差 [SD] 8%),产率为 83%(SD 21%);在不匹配组中,纯度为 97%(SD 3%),产率为 77%(SD 24%)。输注的中位数为 CD3(-)CD56(+) NK 细胞 10.6(SD 7.91)x10(6)个细胞/kg 和 9.21(SD 5.6)x10(6)个细胞/kg。输注的中位数为 CD3(+)CD56(-)T 细胞分别为 0.53(1.1)x10(6)个和 0.27(0.78)x10(6)个,匹配和不匹配组分别为 1 例。仅在匹配组(n = 14)或不匹配组(n = 16)各有 1 例患者发生严重 aGVHD,其他毒性归因于输注的情况很少。具有多次 NK 细胞富集输注和改善的 T 细胞表型恢复的长期反应者具有更好的反应持续时间(p =.0045)和总生存(OS)(P =.0058)。一步法、高产量的过程是可行的,并且输注了高剂量的 NK 细胞,毒性很小。NK 细胞富集 DLI 可改善某些患者的免疫恢复和结果。未来的研究必须评估改善的结果是否是高剂量和改善的 NK 细胞功能的直接结果,还是免疫恢复的其他方面的结果。